These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29207968)

  • 1. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient.
    Berger AK; Haag GM; Ehmann M; Byl A; Jäger D; Springfeld C
    BMC Gastroenterol; 2017 Dec; 17(1):143. PubMed ID: 29207968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis.
    Baldini C; Escande A; Bouché O; El Hajbi F; Volet J; Bourgeois V; Renaut Vantroys T; Ploquin A; Desauw C; Hebbar M
    Pancreatology; 2017; 17(1):146-149. PubMed ID: 28040425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.
    Guion-Dusserre JF; Bertaut A; Ghiringhelli F; Vincent J; Quipourt V; Marilier S; Tharin Z; Bengrine-Lefevre L
    World J Gastroenterol; 2016 Nov; 22(42):9378-9386. PubMed ID: 27895425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
    Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
    Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
    Khushman M; Dempsey N; Maldonado JC; Loaiza-Bonilla A; Velez M; Carcas L; Dammrich D; Hurtado-Cordovi J; Parajuli R; Pollack T; Harwood AP; Macintyre J; Tzeng CW; Merchan JR; Restrepo MH; Akunyili II; Ribeiro A; Narayanan G; Portelance L; Sleeman D; Levi JU; Lima CM; Hosein PJ
    Pancreatology; 2015; 15(6):667-73. PubMed ID: 26412296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.
    Yoo C; Kang J; Kim KP; Lee JL; Ryoo BY; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Kim SC
    Oncotarget; 2017 Jul; 8(28):46337-46347. PubMed ID: 28564637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
    Peddi PF; Lubner S; McWilliams R; Tan BR; Picus J; Sorscher SM; Suresh R; Lockhart AC; Wang J; Menias C; Gao F; Linehan D; Wang-Gillam A
    JOP; 2012 Sep; 13(5):497-501. PubMed ID: 22964956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
    Rubinson DA; Wolpin BM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
    Mahaseth H; Brutcher E; Kauh J; Hawk N; Kim S; Chen Z; Kooby DA; Maithel SK; Landry J; El-Rayes BF
    Pancreas; 2013 Nov; 42(8):1311-5. PubMed ID: 24152956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
    Ghorani E; Wong HH; Hewitt C; Calder J; Corrie P; Basu B
    Oncology; 2015; 89(5):281-7. PubMed ID: 26372905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
    Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of locally advanced pancreatic cancer with FOLFIRINOX].
    Strobel O; Büchler MW
    Chirurg; 2016 Aug; 87(8):699. PubMed ID: 27418266
    [No Abstract]   [Full Text] [Related]  

  • 14. [FOLFIRINOX Combination Chemotherapy in Patients with Metastatic or Recurrent Pancreatic Cancer--A Single Institution Experience].
    Takeda Y; Katsura Y; Ohmura Y; Morimoto Y; Ishida T; Motoyama Y; Ohneda Y; Sato Y; Kuwahara R; Murakami K; Naito A; Kagawa Y; Okishiro M; Takeno A; Egawa C; Kato T; Tamura S
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2360-3. PubMed ID: 26805364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
    Whitehead RP; Benedetti JK; Abbruzzese JL; Ardalan B; Goodwin JW; Balcerzak SP; Samlowski WE; Lenz HJ; Macdonald JS
    Invest New Drugs; 2004 Aug; 22(3):335-41. PubMed ID: 15122082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
    Garcia G; Odaimi M
    J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative Chemotherapy in Elderly Patients with Locally Advanced Adenocarcinoma of the Stomach and the Esophagogastric Junction: A Retrospective Cohort Analysis of Toxicity and Efficacy at the National Center for Tumor Diseases, Heidelberg.
    Haag GM; Byl A; Jäger D; Berger AK
    Oncology; 2017; 92(5):291-298. PubMed ID: 28249280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
    Levy A; Chargari C; Huguet F; Védrine L; Deutsch E
    Pancreas; 2012 Aug; 41(6):973-4. PubMed ID: 22781912
    [No Abstract]   [Full Text] [Related]  

  • 19. [Two cases of pancreatic cancer treated with FOLFIRINOX regimen and G-CSF prophylaxis at the standard therapeutic dose].
    Kiba T; Okada Y; Kajiume S; Yamaguchi A
    Gan To Kagaku Ryoho; 2015 May; 42(5):629-32. PubMed ID: 25981661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
    Hohla F; Hopfinger G; Romeder F; Rinnerthaler G; Bezan A; Stättner S; Hauser-Kronberger C; Ulmer H; Greil R
    Int J Oncol; 2014 Jan; 44(1):319-26. PubMed ID: 24247204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.